Revelation Biosciences, Inc. (NASDAQ:REVB) Short Interest Update

Revelation Biosciences, Inc. (NASDAQ:REVB) was the target of a large decline in short interest in the month of February. As of February 13th, there was short interest totaling 100,079 shares, a decline of 61.2% from the January 29th total of 258,211 shares. Based on an average daily volume of 372,176 shares, the days-to-cover ratio is currently 0.3 days. Currently, 1.6% of the company’s shares are sold short. Currently, 1.6% of the company’s shares are sold short. Based on an average daily volume of 372,176 shares, the days-to-cover ratio is currently 0.3 days.

Revelation Biosciences Price Performance

NASDAQ:REVB opened at $1.32 on Friday. The business’s 50-day moving average is $2.53 and its two-hundred day moving average is $4.92. The firm has a market capitalization of $9.11 million, a PE ratio of -0.02 and a beta of -0.11. Revelation Biosciences has a 12 month low of $1.29 and a 12 month high of $46.31.

Revelation Biosciences (NASDAQ:REVB) last posted its earnings results on Thursday, March 5th. The company reported $15.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.66) by $18.75. Equities analysts anticipate that Revelation Biosciences will post -49.33 EPS for the current year.

Institutional Trading of Revelation Biosciences

Hedge funds have recently made changes to their positions in the company. Armistice Capital LLC boosted its stake in shares of Revelation Biosciences by 442.8% in the fourth quarter. Armistice Capital LLC now owns 434,272 shares of the company’s stock valued at $347,000 after purchasing an additional 354,272 shares during the period. Sabby Management LLC increased its stake in Revelation Biosciences by 192.5% during the 4th quarter. Sabby Management LLC now owns 605,702 shares of the company’s stock worth $484,000 after buying an additional 398,651 shares during the period. Finally, Geode Capital Management LLC acquired a new position in Revelation Biosciences in the 4th quarter worth $27,000. Hedge funds and other institutional investors own 12.80% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e)” rating on shares of Revelation Biosciences in a report on Monday, December 22nd. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Revelation Biosciences currently has a consensus rating of “Sell”.

About Revelation Biosciences

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.